Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumor and among the most lethal cancers. There is increasing evidence that cancer stem cells within GBMs, which are often referred to as glioblastoma stem cells (GSCs), play a critical role in tumor initiation and maintenance. Identification of novel markers for GSCs will lead to better targeting of GSCs which could have tremendous impact on treatment of GBMs. Cell surface markers are particularly suitable as therapeutic targets. Although several promising cell surface markers have successfully been used for enrichment of GSCs, their functional roles in maintenance of GSC properties as well as in GBM formation and development remain to be characterized. In this review, we primarily summarize recent advances in identification of GSC markers, with a particular focus on cell surface markers.
Keywords: Glioblastoma stem cell, cell surface markers, therapeutic target, proteomics
Current Medicinal Chemistry
Title:Targeting Glioblastoma Stem Cells: Cell Surface Markers
Volume: 19 Issue: 35
Author(s): J. He, Y. Liu and D. M. Lubman
Affiliation:
Keywords: Glioblastoma stem cell, cell surface markers, therapeutic target, proteomics
Abstract: Glioblastoma multiforme (GBM) is the most common primary brain tumor and among the most lethal cancers. There is increasing evidence that cancer stem cells within GBMs, which are often referred to as glioblastoma stem cells (GSCs), play a critical role in tumor initiation and maintenance. Identification of novel markers for GSCs will lead to better targeting of GSCs which could have tremendous impact on treatment of GBMs. Cell surface markers are particularly suitable as therapeutic targets. Although several promising cell surface markers have successfully been used for enrichment of GSCs, their functional roles in maintenance of GSC properties as well as in GBM formation and development remain to be characterized. In this review, we primarily summarize recent advances in identification of GSC markers, with a particular focus on cell surface markers.
Export Options
About this article
Cite this article as:
He J., Liu Y. and M. Lubman D., Targeting Glioblastoma Stem Cells: Cell Surface Markers, Current Medicinal Chemistry 2012; 19 (35) . https://dx.doi.org/10.2174/0929867311209066050
DOI https://dx.doi.org/10.2174/0929867311209066050 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Use of Topiceuticals (Topically Applied, Peripherally Acting Drugs) in the Treatment of Chronic Pain
Current Drug Therapy Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design ER Stress and Autophagy
Current Molecular Medicine Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Hypericin and its Derivatives Act as Radiosensitizing Agents That Can Inhibit Tumor Initiating Cell Viability
Clinical Cancer Drugs Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design